Tirzepatide News | Live Feed & Top Stories - 쮸떴눈첵

Tirzepatide

In the last 2 hours

LADbible05:44

In the last 4 hours

The Business Standard05:16

Yesterday

Manchester Evening News13:11 2-Aug-25

Pharmacy Times09:12 2-Aug-25

In the last 7 days

Harvard T.H. Chan School of Public Health15:35 1-Aug-25

Gizmodo14:25 1-Aug-25

Fox News14:16 1-Aug-25

FOX13 Seattle13:55 1-Aug-25

Medpage Today09:40 1-Aug-25

Tyla09:25 1-Aug-25

Clinical Trials Arena07:38 1-Aug-25

STAT04:40 1-Aug-25

Livewire21:32 31-Jul-25

The Financial Express19:17 31-Jul-25

American Journal of Managed Care17:11 31-Jul-25

Pharmacy Times17:09 31-Jul-25

American Journal of Managed Care17:01 31-Jul-25

Pharmaceutical Technology15:38 31-Jul-25

TCTMD14:38 31-Jul-25

The Kansas City Star14:12 31-Jul-25

Pharmaceutical Technology12:55 31-Jul-25

The Conversation (UK)11:36 31-Jul-25

The Economic Times10:07 31-Jul-25

Benzinga09:41 31-Jul-25

Medpage Today09:35 31-Jul-25

American Journal of Managed Care09:24 31-Jul-25

pharmaphorum08:54 31-Jul-25

American Journal of Managed Care08:12 31-Jul-25

PR Newswire (Press Release)06:45 31-Jul-25

The Economic Times20:15 30-Jul-25

American Journal of Managed Care09:08 30-Jul-25

Pharmaceutical Technology07:37 30-Jul-25

WIRED05:13 30-Jul-25

Rock Hill Herald17:19 29-Jul-25

American Journal of Managed Care17:12 29-Jul-25

Benzinga13:35 29-Jul-25

Journal of American Medical Associations11:15 29-Jul-25

Evening Standard10:40 29-Jul-25

Yahoo! UK & Ireland10:26 29-Jul-25

Yahoo! US09:41 29-Jul-25

pharmaphorum09:06 29-Jul-25

Clinical Trials Arena06:13 29-Jul-25

Vizient (Press Release)05:01 29-Jul-25

American Journal of Managed Care22:44 28-Jul-25

American Journal of Managed Care17:48 28-Jul-25

PBS Online17:43 28-Jul-25

Fox News15:19 28-Jul-25

The Economic Times15:12 28-Jul-25

Pharmacy Times14:14 28-Jul-25

Dazed Digital08:24 28-Jul-25

RTT News06:32 28-Jul-25

PR Newswire (Press Release)06:02 28-Jul-25

News-Medical.Net00:23 28-Jul-25

PR Newswire (Press Release)20:22 27-Jul-25

Mint04:42 27-Jul-25

In the last month

Dibesity23:04 26-Jul-25

MailOnline20:25 26-Jul-25

The Motley Fool11:35 26-Jul-25

The Scottish Herald02:53 26-Jul-25

Dibesity22:16 25-Jul-25

FOX13 Seattle16:47 25-Jul-25

Benzinga14:50 25-Jul-25

Charlottesville Daily Progress, Virginia13:39 25-Jul-25

Tyla12:52 25-Jul-25

Pharmacy Times12:16 25-Jul-25

ScienceAlert11:02 25-Jul-25

Aberdeen Live10:43 25-Jul-25

EasternEye07:12 25-Jul-25

McGill Office for Science and Society06:02 25-Jul-25

The Mirror05:52 25-Jul-25

Glasgow Evening Times05:51 25-Jul-25

Knowridge Science Report20:29 24-Jul-25

The Irish News19:18 24-Jul-25

The Independent19:03 24-Jul-25

Dibesity14:24 24-Jul-25

Health Magazine13:43 24-Jul-25

Benzinga11:37 24-Jul-25

Tyla09:31 24-Jul-25

Science News Online09:02 24-Jul-25

Pharmaceutical Technology08:26 24-Jul-25

British Medical Journal05:43 24-Jul-25

The Motley Fool01:57 24-Jul-25

Medpage Today17:15 23-Jul-25

News-Medical.Net14:33 23-Jul-25

LADbible13:46 23-Jul-25

Pharmacy Times12:07 23-Jul-25

Mint11:25 23-Jul-25

Science Blog (Weblog)11:07 23-Jul-25

Zacks10:55 23-Jul-25

Vogue08:04 23-Jul-25

The Cut07:13 23-Jul-25

Knowridge Science Report06:59 23-Jul-25

Korea Biomedical Review06:21 23-Jul-25

News-Medical.Net23:06 22-Jul-25

The Hindu22:39 22-Jul-25

Knowridge Science Report20:28 22-Jul-25

Oprah Daily17:15 22-Jul-25

National Law Review16:24 22-Jul-25

Evening Standard13:11 22-Jul-25

Tyla11:40 22-Jul-25

Daily Sabah08:17 22-Jul-25

PR Newswire (Press Release)08:02 22-Jul-25

LADbible07:03 22-Jul-25

EasternEye06:18 22-Jul-25

The Star, Kenya04:51 22-Jul-25

The Economic Times03:22 22-Jul-25

Manufacturing Chemist02:04 22-Jul-25

The Independent01:41 22-Jul-25

News-Medical.Net00:42 22-Jul-25

Kelowna Capital News19:24 21-Jul-25

LADbible15:55 21-Jul-25

Study Finds15:24 21-Jul-25

The Nittany Turkey (Weblog)14:17 21-Jul-25

TCTMD13:34 21-Jul-25

Pharmacy Times13:13 21-Jul-25

view more headlines

3 Aug 05:44

About our Tirzepatide news

Latest news on Tirzepatide, a drug that is being developed as a potential treatment for obesity and type 2 diabetes. It is a synthetic hormone that is designed to mimic the effects of natural hormones called incretins, which help to lower blood sugar and reduce appetite. Tirzepatide has shown promise in clinical trials, producing significant weight loss in people with obesity or type 2 diabetes. It is administered as a once-weekly injection, and it is believed to work by increasing the production of a hormone called GLP-1, which helps to regulate appetite and insulin production. Tirzepatide is currently in late-stage clinical trials, and it is expected to be considered for regulatory approval in the coming years.

쮸떴눈첵

Tirzepatide

About our Tirzepatide news

Health Top Stories

Lifestyle Top Stories